FDA grants dupilumab Breakthrough Therapy Designation for eosinophilic esophagitis

The designation for this investigational use is based on positive results from Part A of a Phase 3 trial in patients with this chronic and progressive type 2 inflammatory disease that over time, causes scarring and narrowing of the oesophagus, making it difficult to swallow

Source:

Biospace Inc.